Customized lactoferrin-conjugated LNP development services for LRP1/LfR-mediated brain delivery, blood-brain barrier (BBB) transport studies, glioblastoma and brain-tumor cell targeting, ligand density optimization, and payload-compatible formulation screening.
Lactoferrin-conjugated lipid nanoparticles (Lf-LNPs) are lipid nanoparticle delivery systems with the 80 kDa iron-binding glycoprotein lactoferrin (Lf) displayed on the particle surface. Lf binds specifically to low-density lipoprotein receptor-related protein 1 (LRP1) and the lactoferrin receptor (LfR), both of which are highly expressed on brain capillary endothelium, neurons, glioblastoma cells, and several peripheral tumor and immune cell types. Through this receptor-mediated interaction, Lf-modified LNPs can undergo transcytosis across the BBB and accumulate in receptor-positive target cells, providing a dual brain-and-tumor targeting capability.
BOC Sciences supports pharmaceutical and biotechnology researchers developing lactoferrin-modified lipid nanoparticles for siRNA, mRNA, antisense oligonucleotides, plasmid DNA, proteins, peptides, small molecules, and imaging payloads. Our services cover Lf ligand engineering, Lf-lipid conjugate design, LNP surface conjugation, core formulation integration, physicochemical characterization, and receptor-mediated targeting validation, helping clients build lactoferrin-functionalized LNP systems with clearer brain delivery and tumor-targeting performance. We also support targeted LNP development workflows in parallel.
Lactoferrin-Modified LNP Structure Illustration
BOC Sciences supports the full lactoferrin-LNP development workflow, from Lf ligand engineering and Lf-lipid conjugate design to LNP preparation, conjugation, characterization, and LRP1/LfR-mediated targeting validation.
We design and prepare lactoferrin-containing lipid components for targeted LNP formulation. The design can be adjusted by Lf source, fragment selection, lipid anchor, PEG linker length, and surface display strategy.
We introduce lactoferrin ligands onto LNPs using formulation-compatible conjugation methods. The method is selected according to payload type, target receptor, expected ligand density, and the stability needs of the LNP system.
Lactoferrin modification can change particle assembly, surface charge, payload loading, and colloidal stability. We optimize the core formulation and the Lf surface layer together, not as separate steps.
We characterize Lf-modified LNPs to confirm particle quality, Lf conjugation efficiency, payload retention, and formulation consistency. These data help clients compare formulation candidates with clear decision points.
We evaluate whether lactoferrin modification improves uptake and payload function in relevant cell and barrier models. We also design control groups to help separate Lf-related uptake from general nanoparticle uptake.
BOC Sciences supports process development for lactoferrin-modified LNPs. We help improve preparation consistency, Lf insertion efficiency, payload retention, and batch-to-batch comparability.
Selecting the right conjugation chemistry is critical for preserving Lf bioactivity and for placing the protein in a receptor-accessible orientation. BOC Sciences offers a range of Lf-LNP coupling routes so we can match the chemistry to the Lf source, lipid system, and target model rather than applying a single approach to every project.
EDC/NHS chemistry activates carboxyl groups on the LNP lipid (e.g., DSPE-PEG-COOH) to form stable amide bonds with primary amines on the lactoferrin surface. This is one of the most widely used strategies for protein-LNP coupling.
Maleimide-thiol coupling forms a stable thioether bond between a maleimide-functionalized lipid (e.g., DSPE-PEG-MAL) and a thiolated Lf (Lf-SH), giving a more oriented and reproducible protein attachment.
Biotinylated Lf is coupled to avidin- or streptavidin-functionalized LNPs through the high-affinity biotin-(strept)avidin interaction. This is a modular, non-covalent but very strong attachment route.
Lf (isoelectric point ~8.0-8.5) is positively charged at physiological pH, so it can be adsorbed onto negatively charged or anionically functionalized LNP surfaces through electrostatic interaction.
Hydrophobically modified Lf (e.g., Lf-palmitoyl, Lf-stearoyl, or Lf-PEG-lipid) inserts its lipid anchor into the LNP bilayer during or after particle formation, anchoring Lf on the outer leaflet.
Recombinant Lf is genetically fused with a lipid-anchoring motif (e.g., GPI anchor, transmembrane domain, or apolipoprotein tag) so the fusion protein self-anchors into the LNP membrane during formulation.
The choice of Lf source and form affects receptor affinity, batch reproducibility, and downstream performance. BOC Sciences supports a range of Lf ligand options so each project can pick the one that best matches the target receptor profile and experimental design. Below are the major Lf ligand families we routinely work with.
Human lactoferrin (hLf) is the species-matched form for human receptor and disease models. It is preferred for hCMEC/D3, U87 MG, HepG2, and other human cell lines because cross-species differences in receptor binding are minimized. hLf is well characterized for LRP1 and LfR binding, supports BBB transcytosis studies, and is the most translationally relevant ligand for human-target research.
Bovine lactoferrin (bLf) shares high sequence homology with human Lf and is widely available at larger scales. It is commonly used for proof-of-concept studies, large animal work, and cost-sensitive screening campaigns. bLf-LNPs are a practical option for early-stage development where ligand cost and supply matter, while receptor binding is still preserved for many LRP1 and LfR model systems.
Apo-Lf (iron-free) and holo-Lf (iron-saturated) show different conformational states and receptor binding behavior. Apo-Lf tends to expose more basic residues and is often more effective for LRP1 binding, while holo-Lf provides a more compact, stable conformation that can be useful for circulation and storage. Choosing the right iron-loading state is a key formulation lever for Lf-LNP activity.
Short Lf-derived peptides (e.g., LfcinB, lactoferrampin, or the GRRRRSVQWCA-derived sequence) retain the receptor-binding motif of the full protein while being much smaller and easier to conjugate chemically. Peptide-functionalized LNPs are valuable when full-length Lf activity loss is observed, when tighter ligand density control is needed, or when immunogenicity of the full protein is a concern in repeated-dose studies.
Lactoferrin-conjugated LNPs combine receptor-mediated brain and tumor targeting with the intrinsic anti-tumor, anti-inflammatory, and antimicrobial activity of the Lf ligand—delivering payloads via LRP1/LfR recognition while avoiding the immunogenicity risks of antibody conjugates and the cost burden of full-length mAb display.
Lf binds both LRP1 and the classical lactoferrin receptor (LfR), which are co-expressed on brain capillary endothelium and upregulated on many primary and metastatic tumor cells (e.g., glioblastoma, breast, lung, colorectal). This dual receptor profile allows Lf-LNPs to perform transcytosis across the BBB and then bind receptor-positive tumor cells in a single platform, supporting brain delivery and intracranial tumor targeting without the need for a separate brain shuttle and tumor ligand.
Beyond receptor binding, Lf exerts documented anti-tumor, anti-inflammatory, antimicrobial, and immunomodulatory activities. Lf can drive M2-to-M1 repolarization of tumor-associated macrophages, induce ferroptosis-related lipid peroxidation in tumor cells, and modulate NF-κB signaling. As a result, the ligand is not just a targeting address—it can also contribute a second therapeutic mechanism alongside the encapsulated payload, which is rare for surface ligands in this size class.
Lactoferrin is an endogenous human glycoprotein with established metabolic clearance pathways and a well-characterized safety profile, in contrast to antibody ligands (~150 kDa, Fc-related effector functions, batch-to-batch variability) or aptamer ligands (variable nuclease stability, SELEX-dependent). Lf-LNPs therefore offer a clinically tractable targeting ligand with predictable circulation, low intrinsic immunogenicity, and lower cost-of-goods for many research and translational programs.
Lf-PEG-lipid and Lf-PEG-DSPE integrate into standard LNP workflows such as microfluidic mixing, ethanol dilution, and post-insertion methods without disturbing the core ionizable lipid ratio. The PEG spacer keeps Lf exposed at the surface while shielding the particle, supporting reproducible batch production, lyophilization feasibility, and straightforward scale-up for downstream studies.
BOC Sciences develops lactoferrin-modified LNPs for a wide range of payload types used in CNS, glioblastoma, peripheral tumor, and inflammation-related delivery research. Each payload needs a suitable loading strategy, particle design, and functional readout. We help match Lf surface engineering with the payload type and the target-cell model, including lipid nanoparticles for siRNA delivery and lipid nanoparticles for mRNA delivery applications.
| Payload Type | Supported Uses & Lf-LNP Development Considerations | Request Information |
|---|---|---|
| Lf-LNP Development for siRNA | Suitable for LRP1/LfR-positive cell gene-silencing studies, glioblastoma-related target knockdown, and inflammatory pathway research. Development focuses on siRNA encapsulation, free RNA reduction, Lf density, receptor-mediated uptake, and knockdown comparison using matched unmodified LNP controls. | Inquiry |
| Lf-LNP Development for mRNA and Reporter RNA | Designed for reporter expression, therapeutic protein expression, antigen-related delivery, and formulation comparison studies. Development considers mRNA integrity, encapsulation efficiency, Lf surface exposure, particle stability, and expression readouts in LRP1+ glioblastoma, BBB, or hepatocyte models. | Inquiry |
| Lf-LNP Development for Antisense Oligonucleotide (ASO) | Applicable to CNS and tumor cells where ASO-mediated splice modulation or target mRNA degradation is desired. Lf-LNP design supports BBB transport, endosomal release, and target engagement in receptor-positive cells, with matched control LNP for ASO activity comparison. | Inquiry |
| Lf-LNP Development for Plasmid DNA (pDNA) and CRISPR Cargo | Supports non-viral gene delivery in glioblastoma, neuronal, and hepatic models. We evaluate pDNA condensation, ionizable lipid-pDNA balance, Lf surface exposure, and reporter or gene editing readouts in LRP1/LfR-related cell systems. | Inquiry |
| Lf-LNP Development for Protein and Peptide | Suitable for enzyme replacement, peptide hormones, antibody fragments, and other protein payloads used in brain and tumor delivery research. Formulation work focuses on mild loading conditions, aggregation control, activity retention, and Lf-dependent uptake evaluation. | Inquiry |
| Lf-LNP Development for Small Molecule | Designed for hydrophobic, amphiphilic, or weakly basic small molecules used in CNS, glioblastoma, or peripheral tumor research. We consider drug-lipid compatibility, loading method, leakage control, particle stability, Lf modification effect, and release behavior. | Inquiry |
| Lf-LNP Development for Fluorescent and Imaging | Supports fluorescent dyes, DiR/DiD, labeled RNA, labeled proteins, and other tracking payloads used to study Lf-LNP biodistribution, brain uptake, tumor accumulation, and intracellular localization in relevant research models. | Inquiry |
| Lf-LNP Development for Custom Payload | Developed for unusual payloads, multi-payload systems, or early feasibility studies. We evaluate payload compatibility, loading sequence, Lf modification route, particle stability, and target-cell delivery performance. | Inquiry |
Lactoferrin-LNP development often fails when Lf activity, surface density, particle stability, and target-cell biology are not optimized together. BOC Sciences helps solve these issues with data-guided formulation and conjugation development.
✔ Loss of Lactoferrin Activity During Conjugation
Harsh EDC/NHS or glutaraldehyde coupling can denature the 80 kDa Lf protein and destroy its iron-binding cleft or receptor-binding region, leaving the ligand present but non-functional. We screen site-selective chemistries (thiol-maleimide, click chemistry, fusion protein), reaction pH, and stoichiometry to retain Lf secondary structure and receptor binding affinity after conjugation.
✔ Low or Inconsistent Lactoferrin Surface Density
Low Lf density limits receptor engagement, while random coupling produces batch-to-batch variability in surface coverage. We use ELISA, BCA, and SDS-PAGE quantification, combined with controlled Lf-lipid input and post-insertion optimization, to reproducibly hit a target Lf surface density for each project.
✔ Particle Aggregation and Payload Leakage After Conjugation
Lf is a large, basic protein that can bridge particles through electrostatic or hydrophobic interactions, leading to aggregation and premature payload release. We rebalance PEG-lipid content, helper lipid composition, surface charge, and buffer conditions to maintain colloidal stability without sacrificing receptor access.
✔ Limited Receptor-Specific Uptake and Targeting Performance
Lf-LNPs may show modest uptake improvement when surface Lf is hidden by PEG, masked by protein corona, or oriented unfavorably for receptor engagement. We screen linker length, conjugation site, Lf density, and PEG-lipid ratio to expose Lf in a receptor-accessible orientation, supported by brain-targeted LNP development expertise.
✔ Insufficient Transport Across Blood-Brain Barrier Models
Transcytosis across in vitro BBB models (e.g., hCMEC/D3 monolayers) can be low if Lf is not properly oriented, if the LNP is too large, or if the surface charge is unfavorable. We tune particle size, surface charge, Lf density, and PEG shielding, then verify transport using TEER and tracer flux assays.
✔ High Cellular Uptake but Weak Functional Delivery
Strong uptake does not always translate to mRNA expression, siRNA knockdown, or protein activity, because endosomal escape and intracellular release can be limiting. We assess endosomal co-localization, payload release, and functional readouts together to identify and resolve the real bottleneck in the delivery chain.
BOC Sciences helps research teams troubleshoot lactoferrin activity loss, surface density control, payload loading, particle stability, LRP1/LfR mechanism design, and functional delivery readouts.
We start by discussing your payload, target cell or tissue type (brain, glioblastoma, hepatic, pulmonary), receptor background (LRP1, LfR, SPARC), preferred readout, and expected LNP attributes. Based on these details, BOC Sciences prepares a practical Lf-LNP development plan, including Lf source recommendation and receptor model selection.
We design an Lf surface strategy that fits your payload and target receptor model. The design may include Lf source and form selection (human, bovine, apo-, holo-, or peptide), PEG spacer length and chemistry, lipid anchor selection, conjugation route, and Lf density range planning. We also decide whether co-assembly, post-insertion, or surface coupling is the better route, supported by LNP process optimization expertise.
BOC Sciences prepares Lf-LNP candidates using suitable conjugation and formulation methods. We adjust lipid composition, payload loading, mixing conditions, Lf density, PEG-lipid ratio, and post-conjugation buffer exchange. Matched unmodified LNP controls and Lf-blank PEG-LNP controls are also prepared for clean comparison in downstream studies.
Each Lf-LNP candidate is evaluated for particle size, PDI, zeta potential, payload loading, Lf surface density, and formulation integrity. We can also support in vitro BBB transport assays, LRP1/LfR cell uptake, intracellular localization, reporter expression, gene silencing, and in vivo biodistribution in suitable research models, supported by our lipid nanoparticle characterization workflows.
Lactoferrin-conjugated LNPs are used across a wide range of CNS, neuro-oncology, peripheral tumor, and inflammation research. BOC Sciences helps researchers design Lf-LNP systems for the following application areas, with each project tailored to the specific receptor profile and disease model.
Tell us about your application, target cells, and payload requirements. BOC Sciences can help you design, synthesize, optimize, and evaluate customized lactoferrin-conjugated LNPs to meet your research needs.
Challenge: A neuroscience research group was developing an Lf-LNP to deliver a small molecule neuroprotective agent across an in vitro hCMEC/D3 BBB model. Their initial Lf-LNP showed only a modest increase in apical-to-basolateral transport compared with the unmodified LNP, and the formulation was prone to aggregation after 24 h in serum-containing transport buffer.
Diagnosis: BOC Sciences found two main bottlenecks. First, the surface Lf density was too low (around 12 Lf molecules per particle), limiting the opportunity for LRP1 engagement. Second, the chosen PEG-lipid ratio (3 mol%) was leaving Lf partly exposed, but it was also allowing hydrophobic Lf regions to drive particle–particle bridging in serum-containing buffer, causing the aggregation.
Solution: BOC Sciences redesigned the Lf conjugation route using thiol-maleimide chemistry (DSPE-PEG2000-MAL + thiolated Lf) to give a more oriented, site-controlled attachment. We then screened four Lf surface densities (12, 25, 45, and 70 Lf per particle) at three PEG-lipid ratios (1.5, 2.5, and 3.5 mol%) in matched formulations. Candidate LNPs were evaluated for particle size, PDI, Lf density, serum stability, and apical-to-basolateral transport across the hCMEC/D3 monolayer with TEER monitoring.
Result: The selected Lf-LNP carried approximately 45 Lf per particle at 2.5 mol% PEG-lipid, kept the average particle size around 105 nm with PDI below 0.18, and maintained a near-neutral zeta potential (around -8 mV). Apical-to-basolateral transport in the hCMEC/D3 model increased by about 3.2-fold compared with the unmodified LNP, while TEER remained above 180 Ω·cm2 throughout the assay. The client obtained a stable, receptor-engineered Lf-LNP for downstream brain delivery research.
Challenge: An oncology research group was developing an Lf-LNP to deliver a STAT3-targeting siRNA into U87 MG glioblastoma cells. The team's first Lf-LNP showed measurable uptake (around 1.6-fold over unmodified LNP), but the STAT3 mRNA knockdown was below 30% at 48 h, and Lf activity appeared to be reduced after conjugation. The team needed a ligand design that preserved Lf function and improved functional siRNA delivery.
Diagnosis: BOC Sciences reviewed the conjugation route and the formulation. The original EDC/NHS coupling was modifying lysines near the Lf receptor-binding region, reducing Lf-LRP1 affinity. The siRNA encapsulation efficiency was also acceptable, but the ionizable lipid ratio was not optimized for endosomal release, which was limiting the conversion of uptake into knockdown.
Solution: BOC Sciences switched the conjugation to a reductive amination route targeting the glycan region of Lf, which preserved the LRP1-binding interface. We also rebalanced the ionizable lipid and helper lipid content and tested three Lf densities (20, 40, 60 Lf per particle). Particles were evaluated by LRP1 binding assay, U87 MG uptake, endosomal co-localization, and STAT3 mRNA knockdown.
Result: The optimized Lf-LNP maintained an average particle size around 95 nm with PDI below 0.20 and siRNA encapsulation above 88%. LRP1 binding affinity recovered to about 78% of the free Lf reference. U87 MG uptake increased by approximately 2.4-fold versus unmodified LNP, and STAT3 mRNA knockdown improved to around 62% at 48 h. The client received a functionally active Lf-LNP for glioblastoma siRNA research.
Extensive Lipid and Protein Raw Material Portfolio
BOC Sciences maintains a broad inventory of ionizable lipids, helper lipids, cholesterol variants, PEG-lipids, and protein ligands, including human lactoferrin, bovine lactoferrin, apo-Lf, holo-Lf, and a panel of Lf-derived peptides. This allows us to screen Lf sources and lipid combinations efficiently, instead of waiting on third-party supply for each new project.
Advanced Analytical and Characterization Technologies
Our analytical platform covers DLS, zeta potential, HPLC, LC-MS/MS, ELISA, SDS-PAGE, TEM/Cryo-TEM, and fluorescence-based assays, supporting Lf density quantification, conjugation verification, and functional readout for every project.
Integrated Protein Conjugation and LNP Synthesis Platforms
We combine recombinant Lf expression and purification with multiple conjugation routes (EDC/NHS, thiol-maleimide, click chemistry, biotin-avidin, hydrophobic insertion, fusion protein) on a single project, so the Lf chemistry and the LNP formulation are co-developed rather than transferred between teams.
Responsive Technical Support and Project Communication
Each project is assigned a dedicated scientific contact who coordinates the Lf selection, conjugation design, formulation screening, and characterization milestones. Clients receive clear data packages, regular progress updates, and flexible adjustment of the development plan as new data come in.
End-to-End Lactoferrin-LNP Development Services
BOC Sciences supports the full development cycle, from Lf ligand selection and Lf-lipid conjugate design, through LNP formulation and conjugation, to in vitro and in vivo evaluation in CNS, glioblastoma, hepatic, and inflammation models, all under one coordinated workflow.
Lactoferrin is an iron-binding glycoprotein that can interact with receptor systems expressed on certain brain endothelial cells and other target cells. Conjugating lactoferrin to lipid nanoparticles may enhance receptor-associated cellular uptake and support blood-brain barrier (BBB) transport studies. However, increased endothelial uptake does not necessarily mean that nanoparticles successfully cross an intact BBB. Delivery performance depends on lactoferrin surface density, retained protein activity, particle properties, receptor expression, and experimental model selection. Researchers should compare lactoferrin-modified LNPs with unmodified controls and evaluate receptor competition, barrier integrity, transendothelial transport, and functional payload delivery to determine whether lactoferrin modification provides a meaningful targeting advantage.
The most suitable conjugation method depends on lactoferrin structure, available reactive groups, LNP surface chemistry, and the required attachment stability. EDC/NHS-mediated coupling forms stable amide bonds between carboxyl and amino groups, but nonspecific coupling may affect receptor-binding regions. Maleimide-thiol chemistry can provide more controlled attachment when suitable thiol groups are introduced without disrupting important native disulfide bonds. Biotin-avidin bridging offers relatively mild assembly conditions for exploratory ligand presentation studies, whereas electrostatic adsorption is simpler but may be less stable in complex biological media. Researchers should compare conjugation efficiency, protein conformation, retained receptor-binding activity, and nanoparticle stability before selecting a method for further formulation development.
RNA delivery performance depends on the combined optimization of lactoferrin presentation, lipid composition, payload encapsulation, and intracellular release. Insufficient ligand density may limit receptor interaction, while excessive surface coverage can increase aggregation or alter nanoparticle uptake. PEG spacer length, lipid anchoring chemistry, ionizable lipid selection, and formulation conditions also influence particle stability and RNA protection. For siRNA formulations, functional performance should be assessed through target gene silencing. For mRNA formulations, reporter or target protein expression provides a more meaningful functional readout. Fluorescence-based uptake alone cannot establish successful cytoplasmic RNA delivery. Therefore, formulation screening should integrate particle size, PDI, encapsulation efficiency, RNA integrity, receptor-associated uptake, and functional delivery results.
Yes. BOC Sciences supports customized lactoferrin-conjugated LNP development based on the payload type, target cells, intended research application, and delivery requirements. Our services can accommodate siRNA, mRNA, proteins, peptides, small molecules, and other research payloads compatible with lipid-based delivery systems. We help select suitable lipid compositions, encapsulation methods, lactoferrin conjugation strategies, and surface modification conditions according to each payload's physicochemical properties. Formulation screening can address particle uniformity, payload retention, ligand accessibility, and colloidal stability. For unusual or multi-component payloads, we can also evaluate formulation compatibility and development feasibility, helping researchers identify suitable LNP candidates for subsequent characterization and functional studies.
BOC Sciences provides integrated physicochemical characterization and functional evaluation services for lactoferrin-conjugated LNPs. We assess particle size, PDI, zeta potential, payload encapsulation, and formulation stability, together with suitable analytical methods for determining lactoferrin conjugation and surface presentation. Depending on the project, we can evaluate receptor expression, cellular uptake, intracellular localization, and functional payload delivery in selected cell models. For BBB-related research, brain endothelial barrier models can be used to investigate barrier integrity, transendothelial transport, and receptor-associated uptake. Matched unmodified LNP controls and receptor competition experiments can help distinguish nonspecific uptake from lactoferrin-dependent interactions. These results guide formulation refinement and candidate selection.
